Skip to main content
Clinical Trials/NL-OMON30943
NL-OMON30943Not yet recruitingNot Applicable

German Trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-encephalitis (HSVE); a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. - GACHE trial

niversiteit van Heidelberg, afdeling Neurologie0 sites40 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
40

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • Patients with proven HSVE (positive HSV-DNA-PCR); age 18-85 years; focal neurological signs not longer than 5 days prior to admission; informed consent; woman of childbearing potential: negative pregnancy testing in urine.

Exclusion Criteria

  • History of hypersensitivity to corticosteroids; systemic corticosteroid treatment within the last 6 months or at present time; two fixed dilated pupils; pre-event score mRS>2; pregnancy; breast feeding woman; recent history of active tuberculosis or systemic fungal infection; recent head trauma/neurosurgery/peptic ulcer disease; life expectancy < 3 years; participation in another clinical trial; acute viral infections other than HSVE.

Investigators

Sponsor
niversiteit van Heidelberg, afdeling Neurologie

Similar Trials

Active, not recruiting
Phase 1
GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. - GACHEHerpes simplex virus type-1 (HSV-1) is the most frequent cause of fatal sporadic encephalitis in humans. Herpes simplex encephalitis (HSE) was one of the first viral infections to be successfully treated with antiviral drugs. Mortality has been significantly reduced since the introduction of acyclovir, a specific inhibitor of HSV replication. Despite appropriate and promptly initiated antiviral therapy the incidence of persistent neurological deficits remain unacceptably high.
EUCTR2005-003201-81-DEniversitätsklinikum Heidelberg450
Completed
Not Applicable
Trial of aciclovir in the prophylaxis of herpes infections in critical care
ISRCTN29934637Greater Glasgow Health Board (North Glasgow University Hospitals Division) (UK)500
Active, not recruiting
Phase 1
Trial of Aciclovir Prophylaxis of Herpes Infections in Critical Care - TRAPHICCHerpes simplex virus infection - prophylaxis in critically ill patients on ventilators
EUCTR2006-000612-24-GBGreater Glasgow Health Board (North Glasgow University Hospitals Division)500
Completed
Phase 2
Efficacy of antiviral medications in controlling vertigo attacks of patients with Meniere's DiseaseMeniere's disease.Labyrinthine hydrops Ménière's syndrome or vertigo
IRCT138901023597N1Vice Chancellor of Research, Tehran University of Medical Sciences80
Recruiting
Phase 1
Effect of acyclovir therapy on the outcome of mechanically ventilated patients with lower respiratory tract infection and detection of herpes simplex virus in bronchoalveolar lavagePatients in the intensive care unit on invasive mechanical ventilation with pneumonia and detection of herpes simplex virus type 1 (HSV-1) in bronchoalveolar lavage (BAL).
CTIS2023-504322-19-00Friedrich Schiller Universitaet Jena710